Biotechnology companies STORM Therapeutics and AlidaBio have announced a strategic collaboration to accelerate the development of cancer therapies targeting RNA modifications. STORM will utilise AlidaBio’s EpiPlex and EpiScout next-generation sequencing (NGS) platforms to detect and quantitatively measure transcript-specific N6-methyladenosine (m6A) RNA modifications, resulting from METTL3 inhibition. Post-transcriptional modification of RNA, including N6-methyladenosine (m6A), adds a crucial layer of regulation to RNA metabolism, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!